Qyuns Therapeutics
2509.HKSuzhou, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profile2509.HK · Stock Price
HKD 15.60-5.00 (-24.27%)
Market Cap: $445.1M
Historical price data
Overview
Publicly traded biotech developing antibody therapies for autoimmune and allergic diseases with a pipeline targeting IL-4Rα, IL-17A, IL-23, and TSLP pathways.
Immunology
Technology Platform
Integrated R&D system with proprietary rabbit antibody development platform for discovering and optimizing therapeutic antibodies targeting inflammatory pathways.
Opportunities
Growth opportunities include advancing multiple clinical-stage assets in large autoimmune markets, expanding indications for core candidates like QX005N, and securing additional global partnerships for pipeline programs.
Risk Factors
Key risks include clinical trial failures in competitive autoimmune markets, regulatory challenges in China and internationally, and competition from established biologics with strong market positions.
Competitive Landscape
Competes against large pharma companies with established autoimmune biologics (AbbVie, Johnson & Johnson, Novartis) but differentiates through specialized focus on antibody solutions for autoimmune/allergic diseases and bispecific antibody development.